

**AMENDMENT XII TO THE PLAN DOCUMENT OF  
WELFARE FUND OF ENGINEERS LOCAL 513**

The Plan Document of Welfare Fund of Engineers Local 513 Rules and Regulations, Amended and restated as of May 1, 2014, is amended as follows:

1. Effective June 26, 2019, the following paragraph is added to the end of Article XIV:

49. Expenses (medical and/or prescription drug) related to gene therapy. The Plan excludes coverage for all gene therapy procedures, which are health care services that introduce or are related to the introduction of genetic material into a person intended to replace or correct faulty or missing genetic material, whether those therapies have received approval from the U.S. Food and Drug Administration ("FDA"). Some examples of gene therapy include, but are not limited to, Chimeric Antigen Receptor T-Cell ("CAR-T") therapies such as Kymriah and Yescarta, as well as other therapies, such as Luxturna and Zolgensma.

Executed by authority of the Board of Trustees on this 20<sup>th</sup> day of August, 2019:

Timothy J. Sappington  
Chairman

Charles P. Heslin  
Secretary